Submited on: 05 Oct 2010 02:32:41 PM GMT
Published on: 05 Oct 2010 09:54:30 PM GMT
inaccurate information about sneeze-vector article
Posted by Dr. Edlich RF on 09 Apr 2011 09:12:05 PM GMT

1 Is the subject of the article within the scope of the subject category? Yes
2 Are the interpretations / conclusions sound and justified by the data? No
3 Is this a new and original contribution? No
4 Does this paper exemplify an awareness of other research on the topic? No
5 Are structure and length satisfactory? No
6 Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience? Yes
7 Can you suggest any reductions in the paper, or deletions of parts? Yes
8 Is the quality of the diction satisfactory? Yes
9 Are the illustrations and tables necessary and acceptable? Yes
10 Are the references adequate and are they all necessary? No
11 Are the keywords and abstract or summary informative? No
  • Other Comments:

    June 17, 2003 -- The FDA has approved FluMist (influenza virus vaccine live, intranasal), the first influenza vaccine delivered as a nasal mist available in the United States for healthy people.  The FDA pointed out that FluMist, indicated for active immunization for the prevention of disease caused by influenza A and B viruses in healthy children and adolescents, 5-17 years of age, and healthy adults, 18-49 years of age, is manufactured and marketed by MedImmune Vaccines, and is co-marketed by Wyeth Vaccines.  The FDA indicates that FluMist does not protect 100% of individuals vaccinated, or protect against viral strains not represented in the vaccine. It is not indicated for children under 5 years or for adults aged 50 and over. FluMist is contraindicated in persons with hypersensitivity to any component of the vaccine, including eggs; in children and adolescents receiving aspirin therapy or aspirin-containing therapy; in individuals with a history of Guillain-Barre syndrome; and in individuals with known or suspected immune deficiency. The safety and efficacy of FluMist have not been established in pregnant women or for patients with chronic underlying medical conditions, including asthma or reactive airway disease; the vaccine should not be administered to these patients.

    This editorial should not be approved for publication because it doesn’t give detailed information on the FDA indication for FluMist, Flu vaccine, or the documented contra indications to giving this vaccine to patients as listed above. 

  • Competing interests:
  • Invited by the author to review this article? :
  • Have you previously published on this or a similar topic?:
  • References:
    Pandemic preparedness for swine flu influenza in the United States.Edlich RF, Mason SS, Dahlstrom JJ, Swainston E, Long WB 3rd, Gubler K. J Environ Pathol Toxicol Oncol. 2009;28(4):261-4. PMID: 20102323 Update on the National Vaccine Injury Compensation Program. Edlich RF, Olson DM, Olson BM, Greene JA, Gubler KD, Winters KL, Kelley AR, Britt LD, Long WB 3rd. J Emerg Med. 2007 Aug;33(2):199-211. Epub 2007 Jun 18. Review. PMID: 17692778 [PubMed - indexed for MEDLINE] An innovative advance to increase the use of the vaccine information statement. Edlich RF, Olson DM, Olson BM, Greene JA, Gubler KD, Winters KL, Poe MJ, Britt LD, Long WB 3rd. J Emerg Med. 2007 Jul;33(1):81-9. Epub 2007 May 30. PMID: 17630084 [PubMed - indexed for MEDLINE] Rubella and congenital rubella (German measles). Edlich RF, Winters KL, Long WB 3rd, Gubler KD. J Long Term Eff Med Implants. 2005;15(3):319-28. Review. PMID: 16022642 [PubMed - indexed for MEDLINE] [PubMed - indexed for MEDLINE]
  • Experience and credentials in the specific area of science:

    Large extent

  • How to cite:  RF E .inaccurate information about sneeze-vector article[Review of the article 'Sneeze-vector And Sexually Transmitted Vaccines ' by Egeth M].WebmedCentral 2011;2(4):WMCRW00654
1 2 3 4 5 6 7 8 9
Report abuse